Washington, DC (June 30, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Brian Toohey will join the association as senior vice president for international advocacy. Toohey returns to PhRMA on July 11, 2016.
A recognized leader in international advocacy and economic policy, Toohey is former president and CEO of the Semiconductor Industry Association (SIA), where he led the semiconductor industry’s federal advocacy, international trade and technology programs. Prior to joining SIA, Toohey spent nearly eight years at PhRMA, starting as the lead international lobbyist in the federal advocacy department and then serving as leader of PhRMA’s international advocacy team. He previously worked at the U.S. Department of Commerce, focusing on European trade and intellectual property issues, and was an executive in the wireless telecommunications industry.
“As the biopharmaceutical industry develops bold new treatments that save and improve lives, Brian’s proven leadership skills and deep experience in international health policy and advocacy will help get these medicines to patients who need them around the world,” said Stephen J. Ubl, president and CEO of PhRMA. “He has a strong track record of working effectively with international governments, multilateral organizations and global stakeholders to ensure greater patient access to the breakthrough therapies pioneered by PhRMA member companies.”
Toohey currently serves on the U.S. Department of Homeland Security Science and Technology Advisory Committee, previously served on the U.S. Department of Commerce and U.S. Trade Representative’s Industry Trade Advisory Committee and is an adjunct professor at the Georgetown University School of Foreign Service.
“The biopharmaceutical industry is transforming lives around the world every day, and the promise for future cures is brighter than ever,” said Toohey. “I am passionate about this industry and am thrilled to have the opportunity to again lead the outstanding PhRMA international team to ensure the strongest possible advocacy for patients and innovation.”
Toohey comes to PhRMA most recently from DEKA Research & Development Corporation, a New Hampshire-based medical technology company, where he is executive vice president.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.